Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026
News > Business News
Audio By Carbonatix
7:00 AM on Tuesday, February 17
The Associated Press
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Feb 17, 2026--
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its fourth quarter and full-year 2025 financial results on Tuesday, March 3, 2026, after the U.S. financial markets close.
Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management’s remarks.
To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here.
Following the completion of the call, a telephonic replay can be accessed by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international) and using conference number 13758456. An archived webcast can also be accessed on the Investor Relations page of the Evolus website at www.evolus.com.
About Evolus, Inc.
Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau ® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse ™, a collection of unique injectable hyaluronic acid (HA) gels. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.
Jeuveau ® and Nuceiva ® are registered trademarks and Evolysse ™ is a trademark of Evolus, Inc.
View source version on businesswire.com:https://www.businesswire.com/news/home/20260217251838/en/
CONTACT: Investors:
Nareg Sagherian, Vice President, Head of Global Investor Relations and Corporate Communications
Phone: (248) 202-9267
Email:[email protected]
Media:
Email:[email protected]
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: WOMEN PHARMACEUTICAL HEALTH CONSUMER LUXURY COSMETICS RETAIL OTHER HEALTH
SOURCE: Evolus
Copyright Business Wire 2026.
PUB: 02/17/2026 08:00 AM/DISC: 02/17/2026 08:00 AM
http://www.businesswire.com/news/home/20260217251838/en
